Back to today’s briefing

Story perspectives

Warning: Mislabeling of Lercanidipine Puts 7,700 Patients at Risk

4/18/2025

33 6

Summary

Story summary

British regulators have issued a crucial warning regarding a mislabeling issue with lercanidipine hydrochloride tablets, where 20mg packs were incorrectly marked as 10mg. This error could result in dangerous double dosing for over 7,700 patients. Individuals are urged to verify their medication and consult healthcare professionals if they have any doubts. Recordati Pharmaceuticals is taking action by recalling undelivered packages.

1 of 1

Story summary

British regulators have issued a crucial warning regarding a mislabeling issue with lercanidipine hydrochloride tablets, where 20mg packs were incorrectly marked as 10mg. This error could result in dangerous double dosing for over 7,700 patients. Individuals are urged to verify their medication and consult healthcare professionals if they have any doubts. Recordati Pharmaceuticals is taking action by recalling undelivered packages.